Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EYPT | US
0.42
5.12%
Healthcare
Biotechnology
30/06/2024
04/10/2024
8.63
8.50
8.70
8.29
EyePoint Pharmaceuticals Inc. a pharmaceutical company engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States China and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company's pipeline leverages its Durasert technology for sustained intraocular drug delivery including EYP-1901 an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals Inc. in March 2018. EyePoint Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Watertown Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
51.5%1 month
52.6%3 months
75.9%6 months
96.0%-
-
1.87
0.10
0.07
-11.49
3.38
-
-96.53M
461.86M
461.86M
-
-364.52
-
4.10
-60.81
15.38
19.94
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.55
Range1M
2.11
Range3M
3.84
Rel. volume
0.45
Price X volume
2.30M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
SIGA Technologies Inc | SIGA | Biotechnology | 6.98 | 498.16M | 0.87% | 5.95 | 0.97% |
CorMedix Inc | CRMD | Biotechnology | 8.9 | 497.15M | 7.62% | n/a | 1.29% |
Emergent BioSolutions Inc | EBS | Biotechnology | 9.35 | 494.68M | 1.74% | n/a | 226.97% |
KalVista Pharmaceuticals Inc | KALV | Biotechnology | 11.36 | 490.93M | -4.05% | n/a | 3.62% |
PureTech Health plc | PRTC | Biotechnology | 20.33 | 486.74M | 5.39% | n/a | 29.73% |
REGENXBIO Inc | RGNX | Biotechnology | 9.72 | 480.39M | -2.02% | n/a | 45.57% |
Anavex Life Sciences Corp | AVXL | Biotechnology | 5.595 | 474.43M | -1.06% | n/a | 0.00% |
OABI | OABI | Biotechnology | 3.99 | 471.47M | -1.97% | n/a | 8.27% |
Valneva SE | VALN | Biotechnology | 5.8116 | 471.18M | 1.78% | n/a | 126.08% |
Ginkgo Bioworks Holdings Inc. | DNA | Biotechnology | 8.33 | 462.94M | 8.04% | n/a | 54.29% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -11.49 | 0.76 | Cheaper |
Ent. to Revenue | 3.38 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.87 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 75.93 | 74.67 | Par |
Debt to Equity | 0.10 | -1.82 | Expensive |
Debt to Assets | 0.07 | 0.26 | Cheaper |
Market Cap | 461.86M | 3.73B | Emerging |